

commercial interest or from small companies may need special attention to ensure that testing occurs without delay. Policies that affect, or are intended to substitute for, private-sector involvement in ensuring vaccine development and supply should be based on thorough analysis and consultation. The National Vaccine Program Office now plans increased consultations with industry as originally envisioned under P.L. 99-660. Such consultation with the private sector is a priority for FY 1994 and FY 1995 to strengthen future iterations of the National Vaccine Plan (see section IX).